Article
Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.
Pigment cell & melanoma research - 1 Nov 2025
Tellenbach Flavia L, Seiler Luzia, Johnson Mark, Rehrauer Hubert, Schukla Prachi, Martinez-Gomez Julia, Stoffel Corinne I, Kamal Adeela, Dummer Reinhard, Levesque Mitchell P, Eichhoff Ossia M
Abstract excerpt
Metastatic melanoma, the most aggressive form of skin cancer, accounts for the majority of skin cancer-related deaths. While targeted kinase inhibitors have improved outcomes for patients with BRAF-mutated melanomas, their efficacy is often short-lived, and effective treatments for other mutation...
Topics
- Melanoma
- Humans
- Animals
- Cell Line, Tumor
- GTP Phosphohydrolases
- Mutation
- Membrane Proteins
- Protein Kinase Inhibitors
- Benzimidazoles
- Antineoplastic Combined Chemotherapy Protocols
- Xenograft Model Antitumor Assays
- Mice
- Cell Proliferation